Proffered Papers
1221
POSTER
Chemical-genetic Screenings for Synthetic-lethal Interactions in
Breast Cancer
D. Soncini1 , I. Caffa1 , G. Zoppoli1 , F. Patrone1 , A. Ballestrero1 ,
A. Nencioni1 . 1 University of Genoa, DI.M.I, Genoa, Italy
Background: Breast cancer (BC) has a huge epidemiological impact in
developed countries and is a leading cause of cancer-related mortality
among women. Despite progresses made in diagnosis and treatment,
especially in its advanced or metastatic presentation, it is hardly curable.
This is mostly due to the paucity of therapeutics that specifically target BC’s
genetic and phenotypic peculiarities. Synthetic-lethal therapeutics exploit
cancer-associated mutations as Achilles’ heels by taking advantage of
the weaknesses that such mutations expose in malignant cells (i.e, PARP
inhibitors for BRCA1/2-mutated cancers). Here, we report on the execution
of chemical-genetic interaction screens aimed to identify compounds that
specifically kill mammary epithelial cells engineered to express common
BC-associated mutations.
Material and Methods: MCF10A, a spontaneously immortalized but
non-transformed human mammary epithelial cell line, was engineered to
express HRas, Her2/neu, PI3K H1047R or to stably silence the tumour
suppressors PTEN, p53 and Rb. Cells engineered with empty retroviral
vectors were used as controls. The introduced genetic modifications were
verified by western blotting and by flow cytometry. The so-generated
isogenic cells lines were probed against different collections of chemical
compounds (including the Diversity and Mechanistic set from NIH’s NCI
Developmental Therapeutics Program) for a total of more than 10.000
genotype-compound combinations. Viability was assessed by colorimetric
assay after a 48h-incubation. The experiments were performed in a 384well format by means of a robotic liquid handling workstation.
Results: We developed a system to perform chemical-genetic screens in
genetically-modified epithelial breast cells. Our approach is able to detect
susceptibility phenotypes, since MCF10A cell engineered to overexpress
HER2 do show a markedly increase susceptibility to Lapatinib, a dual
EGFR/HER2 tirosine kinase inhibitor which is known to preferentially
kill HER2-over-expressing cells. Moreover, previously reported resistance
phenotypes due to aberrant activation of the PI3K-Akt and MAPK pathway
were also readily detected in preliminary experiments.
Conclusions: We aim to identify synthetic-lethal compounds that may
serve as leads for subsequent development of clinically-effective treatments
for BC. The use of this type of chemical-genetic approach appears to be
feasible and able to detect mutation-associated susceptibility phenotypes.
1222
POSTER
Chemical Screening for Potentiators of Lapatinib Activity in Human
Breast Cancer
I. Caffa1 , D. Soncini1 , G. Zoppoli1 , E. Moran1 , F. Patrone1 , A. Ballestrero1 ,
A. Nencioni1 . 1 University of Genova, Department of Internal Medicine,
Genova, Italy
Background: 10−30% of breast cancers overexpress the oncogenic
receptor tyrosine kinase HER2 as a consequence of gene amplification.
In these tumours, HER2 acts as a driving oncogene which cancer cells
are addicted to. Monoclonal antibodies against HER2 and small-molecule
inhibitors of its tyrosine kinase activity proved effective in the treatment of
HER2+ breast cancer. However, the benefit of these treatments is limited
by primary and acquired resistance. Lapatinib is an inhibitor of the tyrosine
kinase activity of both HER2 and EGFR and it is highly active against
HER2-overexpressing breast cancers. Resistance to lapatinib in breast
cancer is due to estrogen-dependent pro-survival mechanisms, and to
activating mutations in the PI3K and ras pathways. We chose lapatinib as a
drug model and performed chemical screens in order to identify compounds
which synergistically enhance lapatinib efficacy in breast cancer cells.
Materials and Methods: The HER2+ overexpressing breast cancer cell
line SKBR3 was used in our experiments. Cells were incubated in the
presence or absence of lapatinib, and subsequently probed against the
over 2000 compounds of the Mechanistic Set and the Diversity Set from
NCI/NHI Developmental Therapeutic Program. Cells were plated in 384
well plates and 4 different concentration of each compound were tested.
After 72h of incubation, cell viability was determined using a colorimetric
assay and then the cooperative index (CI) was calculated as the sum of the
specific cell deaths induced by the single agents divided by the specific cell
death in response to their combination. CI values <1, indicate a synergistic
effect between compounds.
Results: We identified 13 different compounds which showed a synergistic
activity with lapatinib in SKBR3 cells. Most of these show antiproliferative
activity in vitro in NCI-60 cell lines, but their molecular target is unknown.
These compound were retested and 9 of them confirmed to synergistically
potentiate the activity of the tyrosine kinase inhibitor. Follow-up experiments
S151
are now ongoing with the aim to define their mode of action and their
usefulness in combination regimens.
Conclusions: Our preliminary results show that lapatinib activity can be
potentiated in combination with compounds identified through chemical
screens. Such drug combinations shall be further investigated and may
lead to new treatment strategies for HER2-overexpressing malignancies.
1223
POSTER
Enhanced Cellular Delivery of Idarubicin by Surface Modification
of Propyl Starch Nanoparticles Employing Pteroic Acid Conjugated
Polyvinyl Alcohol
J. Ratnesh1 , P. Dandekar1 , B. Loretz1 , A. Melero2 , T. Stauner3 , G. Wenz3 ,
M. Koch4 , C.M. Lehr1 . 1 Helmholtz Institute of Pharmaceutical Research
Saarland (HIPS), Department of Drug Delivery, Saarbrücken, 2 Saarland
University, Department of Biopharmaceutics and Pharmaceutical
Technology, Saarbrücken, 3 Saarland University, Organic Macromolecular
Chemistry, Saarbrücken, 4 INM − Leibniz Institute for New Materials,
Service Group Physical Analysis, Saarbrücken, Germany
Background: Improved efficacy of anti-cancer agents with simultaneous
reduction of their systemic exposure and non-specific toxicity is possible
through enhanced internalization of nanoparticles encapsulating these. The
routinely used hydrophilic stabilizers used in formulating nanoparticles may
however hinder their interaction with the hydrophobic cell membranes.
The present investigation attempts to overcome this problem by employing
pteroic acid modified polyvinyl alcohol (ptPVA) as a novel surfactant to
formulate idarbicin (IDA) encapsulated propyl starch nanoparticles [1]. This
modification was hypothesized to enhance their uptake through improved
adsorption of various proteins, the receptors of the latter being dominant
on numerous cancer cells.
Materials and Methods: IDA-loaded ptPVA nanoparticles were formulated
using solvent emulsification-diffusion technique and optimized for relative
amounts of drug to polymer and stabilizer. The optimum formulation was
characterized with regards to particle size, surface charge, morphology,
drug encapsulation and loading and in vitro release pattern. Enhanced
protein adsorption of ptPVA modified nanoparticles was confirmed
employing BCA assay with BSA as the standard. The safety and efficacy of
the nanoparticles was confirmed by MTT and ATPase cytotoxicity assays
in Caco-2 cell line. Enhancement of cellular uptake was confirmed using
Confocal laser scanning microscopy.
Results: A homogenous distribution of spherical IDA nanoparticles (245
nm) were formulated with IDA encapsulation of about 85%. These
nanoparticles which exhibited a controlled drug release were found
to be safe for cellular evaluations in both the cytotoxicity assays.
Moreover an enhanced efficacy of the IDA nanoparticles was observed
as compared to the free drug control thus indicating their efficacy. Higher
protein binding was exhibited by ptPVA nanoparticles compared to nonmodified ones indicating the possible influence of protein adsorption on
improved internalization and hence efficacy. Furthermore, a higher cellular
internalization was observed for ptPVA nanoparticles in HT-29 cells and
A-549 cells, thus confirming the proposed hypothesis of higher protein
adsorption being responsible for this effect.
Conclusion: Higher uptake and efficacy along with cellular safety indicate
the potential of the IDA nanoparticles for in vivo evaluations to validate
these results. Such selective internalization and efficacy in cancer cells is
significant for toxic anti-cancer drugs like IDA.
Acknowledgements: German Bundesministerium für Bildung und Forschung (BMBF) program “NanoStarch” project number 13N9133, Mr. Leon
Mujis for technical assistance.
References
[1] Santander-Ortega, M. J.; Stauner, T.; Loretz, B.; Ortega-Vinuesa, J.
L.; Bastos-González, D.; Wenz, G.; Schaefer, U. F.; Lehr, C. M.
Nanoparticles made from novel starch derivatives for transdermal drug
delivery. J. Control Release 2010, 141, 85−92.
1224
POSTER
Docetaxel Delivery Mediated by Nanoparticles of Novel Hydrophobic
Starch
P. Dandekar1 , R. Jain1 , T. Stauner2 , B. Loretz1 , M. Koch3 , G. Wenz2 ,
C.M. Lehr1 . 1 Helmholtz Institute of Pharmaceutical Research Saarland
(HIPS), Department of Drug Delivery, Saarbrücken, 2 Saarland University,
Organic Macromolecular Chemistry, Saarbrücken, 3 INM − Leibniz Institute
for New Materials, Service Group Physical Analysis, Saarbrücken,
Germany
Background: Polymeric nanoparticles can overcome challenges in delivery
of anti-cancer agents due to their enhanced internalization, retention and